Data from the first analysis of the The Prostate Cancer Registry are being presented at the 2015 European Cancer Congress (ECC) in Vienna, Austria.

The Registry is the first and largest prospective study of patients with metastatic castration-resistant prostate cancer (mCRPC) in Europe.

It aims to provide real world data to help improve the quality of care for men with mCRPC.

With the aim of enrolling a total of 3,000 patients, to date, more than 2,500 mCRPC patients from 192 centres in 16 European countries have so far been enrolled.

Patients in the study will be followed for up to three years.

By collecting real world data from such a large patient population in both oncology and urology clinics, the Registry has the capacity to address the key medical and scientific questions concerning the optimal care of mCRPC patients in routine practice, such as treatment sequencing, treatment outcomes, impact on quality of life, medical resource utilisation and patient safety.

“Whilst the advent of new, effective treatments has benefitted many patients, for doctors, increased treatment options raise more questions about which are the right treatments to give individual patients and in what order,” said Dr Simon Chowdhury, Guy’s Hospital, London.

“The Registry follows patients we see in every day practice – patients with multiple co-morbidities such as heart disease and diabetes. The size and scope of the Registry will allow us to analyse large-scale datasets to better understand how we can best utilise the various therapeutic options and tailor treatment to our patients’ individual needs. As the database matures, we can expect to keep building our knowledge on contemporary mCPRC management in daily practice.”

The first analysis presented at ECC2015 indicates an enrolment of a broad range of patients with complex clinical presentations, reflecting the real-world nature of the population studied.

Patients in the study have a mean age of 71.5 years and a high incidence of comorbidities (62.8%), the most common being cardiovascular disease (54.9%) and hypertension (44.6%).

79.2% of the patients enrolled were prescribed concomitant medications.

41.4 per cent of patients had previously received chemotherapy and 58.6 per cent were chemotherapy-naïve at enrolment.

Further analyses and data releases are being planned for early 2016.

Jane Griffiths, Company Group Chairman, Janssen Europe, the Middle East and Africa (EMEA) said: “The Prostate Cancer Registry is a landmark observational study which Janssen is proud to be supporting. We expect The Registry to offer a fuller picture of the evolution of mCRPC management in routine practice. We anticipate the knowledge it provides will help to improve the care of patients with advanced prostate cancer.”

Prostate cancer is the most commonly diagnosed cancer in men, with over 400,000 new cases diagnosed in Europe each year.2 Latest prostate cancer figures show that there are currently three million men living with the disease in Europe.

Source: Janssen